Astellas Balks On Vibativ License, But Focus Shifts To Tivozanib And MDV3100
This article was originally published in PharmAsia News
Astellas terminates Vibativ license after just one year on the market to allocate resources for urology and transplantation while focus shifts to Phase III oncology drugs.
You may also be interested in...
Aveo/Astellas’ triple VEGF inhibitor tivozanib hit its progression-free survival endpoint of superiority over Onyx/Bayer’s Nexavar (sorafenib), but the question remains whether a three-month PFS advantage can confer first-line market superiority.
The US Department of Justice, SEC and the Chinese government have all increased investigations of corrupt practices, and incriminating evidence is easier than ever to find. What can companies do to protect themselves?
Astellas’ geographic and indication expansion strategy for Xtandi matches patent losses in Japan.